Literature DB >> 23578923

Irisin levels correlate with energy expenditure in a subgroup of humans with energy expenditure greater than predicted by fat free mass.

Andrew G Swick1, Stephen Orena, Annalouise O'Connor.   

Abstract

OBJECTIVE: Obesity is a result of chronic overconsumption of calories relative to the amount of energy expended. While fat free mass can account for ~80% of the variance in energy expenditure, there is still considerable variability in energy requirements between individuals that cannot be explained. We hypothesized that responsiveness to the recently discovered myokine, irisin, which has been touted to increase energy expenditure via activation of brown adipocytes in rodents and possibly humans, may explain some of the variability in energy expenditure. MATERIALS/
METHODS: Post-menopausal women (n=17) spent 24-h in a whole room indirect calorimeter. During the study day, subjects remained sedentary and consumed meals tailored to their energy requirements. Plasma irisin, leptin and adiponectin were measured in samples taken from each subject.
RESULTS: Our results suggest that in general, irisin levels do not correlate with 24-h energy expenditure, however, for a subpopulation irisin levels and energy expenditure are highly correlative.
CONCLUSION: Irisin may help explain some of the observed variability in individual energy requirements that cannot be accounted for by fat free mass. Therefore, interventions designed to increase irisin action may prove to be promising avenues for the treatment of obesity.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BAT; BMI; DXA; EE; FFM; FM; FNDC5; Indirect calorimetry; PGC-1α; RQ; VCO(2); VO(2); body mass index; brown adipose tissue; dual x-ray absorptiometry; energy expenditure; fat free mass; fat mass; fibronectin type III domain containing 5; peroxisome proliferator-activated receptor γ coactivator-1α; respiratory quotient; volume CO(2) expired (liters/min); volume oxygen consumed (liters/min)

Mesh:

Substances:

Year:  2013        PMID: 23578923     DOI: 10.1016/j.metabol.2013.02.012

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  30 in total

1.  Genetic variation in lean body mass, changes of appetite and weight loss in response to diet interventions: The POUNDS Lost trial.

Authors:  Xiang Li; Tao Zhou; Hao Ma; Yoriko Heianza; Catherine M Champagne; Donald A Williamson; George A Bray; Frank M Sacks; Lu Qi
Journal:  Diabetes Obes Metab       Date:  2020-08-20       Impact factor: 6.577

2.  Circulating irisin in relation to insulin resistance and the metabolic syndrome.

Authors:  Kyung Hee Park; Lesya Zaichenko; Mary Brinkoetter; Bindiya Thakkar; Ayse Sahin-Efe; Kyoung Eun Joung; Michael A Tsoukas; Eleni V Geladari; Joo Young Huh; Fadime Dincer; Cynthia R Davis; Judith A Crowell; Christos S Mantzoros
Journal:  J Clin Endocrinol Metab       Date:  2013-09-20       Impact factor: 5.958

3.  Exercise training does not increase muscle FNDC5 protein or mRNA expression in pigs.

Authors:  John N Fain; Joseph M Company; Frank W Booth; M Harold Laughlin; Jaume Padilla; Nathan T Jenkins; Suleiman W Bahouth; Harold S Sacks
Journal:  Metabolism       Date:  2013-07-05       Impact factor: 8.694

4.  Diet quality is associated with circulating C-reactive protein but not irisin levels in humans.

Authors:  Kyung Hee Park; Lesya Zaichenko; Patricia Peter; Cynthia R Davis; Judith A Crowell; Christos S Mantzoros
Journal:  Metabolism       Date:  2013-10-29       Impact factor: 8.694

5.  Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies.

Authors:  Timea Kurdiova; Miroslav Balaz; Marek Vician; Denisa Maderova; Miroslav Vlcek; Ladislav Valkovic; Miroslav Srbecky; Richard Imrich; Olga Kyselovicova; Vitazoslav Belan; Ivan Jelok; Christian Wolfrum; Iwar Klimes; Martin Krssak; Erika Zemkova; Daniela Gasperikova; Jozef Ukropec; Barbara Ukropcova
Journal:  J Physiol       Date:  2013-12-02       Impact factor: 5.182

6.  Leptin administration in physiological or pharmacological doses does not alter circulating irisin levels in humans.

Authors:  A Gavrieli; G Panagiotou; C S Mantzoros
Journal:  Int J Obes (Lond)       Date:  2016-05-20       Impact factor: 5.095

7.  Irisin improves fatty acid oxidation and glucose utilization in type 2 diabetes by regulating the AMPK signaling pathway.

Authors:  C Xin; J Liu; J Zhang; D Zhu; H Wang; L Xiong; Y Lee; J Ye; K Lian; C Xu; L Zhang; Q Wang; Y Liu; L Tao
Journal:  Int J Obes (Lond)       Date:  2015-09-25       Impact factor: 5.095

8.  Irisin mRNA and circulating levels in relation to other myokines in healthy and morbidly obese humans.

Authors:  Maria T Vamvini; Konstantinos N Aronis; Grigorios Panagiotou; Joo Young Huh; John P Chamberland; Mary T Brinkoetter; Michael Petrou; Costas A Christophi; Stefanos N Kales; David C Christiani; Christos S Mantzoros
Journal:  Eur J Endocrinol       Date:  2013-10-21       Impact factor: 6.664

9.  Circulating irisin levels and coronary heart disease: association with future acute coronary syndrome and major adverse cardiovascular events.

Authors:  K N Aronis; M Moreno; S A Polyzos; J M Moreno-Navarrete; W Ricart; E Delgado; J de la Hera; A Sahin-Efe; J P Chamberland; R Berman; A Spiro; P Vokonas; J M Fernández-Real; C S Mantzoros
Journal:  Int J Obes (Lond)       Date:  2013-06-11       Impact factor: 5.095

10.  Pharmacological concentrations of irisin increase cell proliferation without influencing markers of neurite outgrowth and synaptogenesis in mouse H19-7 hippocampal cell lines.

Authors:  Hyun-Seuk Moon; Fadime Dincer; Christos S Mantzoros
Journal:  Metabolism       Date:  2013-05-07       Impact factor: 8.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.